Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity

Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity

Bibliographic Details
Main Authors:	Barbara Barbaro, Ilaria Romito, Anna Alisi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-10-01
Series:	Frontiers in Genetics
Subjects:	NAFLD (non-alcoholic fatty liver disease) NASH (non-alcoholic steatohepatitis) Phf2 histone modification epigenetics (MeSH)
Online Access:	https://www.frontiersin.org/article/10.3389/fgene.2018.00443/full

Similar Items

Plasma Levels of Homocysteine and Cysteine Increased in Pediatric NAFLD and Strongly Correlated with Severity of Liver Damage
by: Anna Pastore, et al.
Published: (2014-11-01)

NAFLD: Challenges and opportunities to address the public health problem in Latin America
by: Juan Pablo Arab, et al.
Published: (2021-09-01)

Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD
by: Victoria Svop Jensen, et al.
Published: (2021-02-01)

Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
by: Clémence Rives, et al.
Published: (2020-12-01)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
by: Martina Colognesi, et al.
Published: (2020-07-01)

Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD)
by: Xin Xin, et al.
Published: (2019-09-01)

Mineralocorticoid receptor modulation by dietary sodium influences NAFLD development in mice
by: Daniel Cabrera, et al.
Published: (2021-09-01)

A case of metabolic syndrome, positive antinuclear antibodies and cirrhosis.
by: Alessandro Grasso
Published: (2007-09-01)

Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease
by: Chao Sun, et al.
Published: (2015-03-01)

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
by: Stephen Caldwell
Published: (2017-06-01)

EPIDEMIOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE IN NOVOSIBIRSK (SIBERIAN FEDERAL DISTRICT): REGIONAL DATA OF OPEN MULTICENTER PROSPECTIVE STUDY DIREG 2
by: V. V. Tsukanov, et al.
Published: (2016-09-01)

PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY)
by: D. Kh. Kalimullina, et al.
Published: (2017-03-01)

Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis
by: Nicha Wongjarupong, et al.
Published: (2017-12-01)

Treatments for NAFLD: State of Art
by: Alessandro Mantovani, et al.
Published: (2021-02-01)

Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease
by: Linda A. Ban, et al.
Published: (2016-03-01)

Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
by: Yang Xiao, et al.
Published: (2021-08-01)

NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL
by: D. V. Blinov
Published: (2015-12-01)

Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern
by: Ekta Dhamija, et al.
Published: (2019-01-01)

Epigenetic Mechanisms Underlying the Link between Non-Alcoholic Fatty Liver Diseases and Nutrition
by: Joo Ho Lee, et al.
Published: (2014-08-01)

Presence and Implications of Sarcopenia in Non-Alcoholic Steatohepatitis
by: Gregory Habig, et al.
Published: (2021-04-01)

Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis
by: Adnan Said, et al.
Published: (2017-07-01)

NASH and cryptogenic cirrhosis: A histological analysis†† Financial Support/Grants: This research supported in part by the Intramural Research Program of the NIH, National Cancer Institute.
by: Stephen H. Caldwell, et al.
Published: (2009-10-01)

Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile
by: Helma P. Cotrim, et al.
Published: (2011-01-01)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
by: Hyunmi Kim, et al.
Published: (2021-04-01)

Involvement of a periodontal pathogen, <it>Porphyromonas gingivalis </it>on the pathogenesis of non-alcoholic fatty liver disease
by: Yoneda Masato, et al.
Published: (2012-02-01)

Can Walnut Serve as a Magic Bullet for the Management of Non-Alcoholic Fatty Liver Disease?
by: Mi-Young Kim, et al.
Published: (2021-12-01)

The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies
by: Umar Hayat, et al.
Published: (2021-01-01)

Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the pastKey points
by: Oyekoya T. Ayonrinde
Published: (2021-06-01)

Non Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure
by: Alabagi Abdulla, et al.
Published: (2016-04-01)

Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis
by: Javier Ampuero, et al.

Structural basis for histone variant H3tK27me3 recognition by PHF1 and PHF19
by: Cheng Dong, et al.
Published: (2020-09-01)

Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis
by: Shui-Xian Du, et al.
Published: (2017-12-01)

Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders
by: Federica Saponaro, et al.
Published: (2020-07-01)

Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases
by: Maite Martínez-Uña, et al.
Published: (2020-12-01)

The Connection between MicroRNAs from Visceral Adipose Tissue and Non-Alcoholic Fatty Liver Disease
by: Veronika Zubáňová, et al.
Published: (2021-04-01)

Vitamins and non-alcoholic fatty liver disease: A molecular insight
by: Sana Raza, et al.
Published: (2021-06-01)

Regulation of hepatic genes related to lipid metabolism and antioxidant enzymes by sodium butyrate supplementation
by: Kazue Honma, et al.
Published: (2020-09-01)

Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD
by: Annelise M. Poss, et al.
Published: (2020-07-01)

Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
by: Anne Fougerat, et al.
Published: (2020-07-01)

Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis
by: Sang R. Lee, et al.
Published: (2018-10-01)